Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery

Journal of Thoracic and Cardiovascular Surgery

Volumn 132, Issue 6, 2006, Pages 1420-1425

  Shim, Jae Kwang ^a   Choi, Yong Seon ^a   Oh, Young Jun ^a   Kim, Dae Hee ^a   Hong, Yong Woo ^a   Kwak, Young Lan ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ISOFLURANE; MIDAZOLAM; NEUROMUSCULAR BLOCKING AGENT; PLACEBO; ROCURONIUM; SILDENAFIL; SUFENTANIL; VECURONIUM;

ADULT; ANESTHESIA INDUCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART HEMODYNAMICS; HEART VALVE SURGERY; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; VALVULAR HEART DISEASE; VASCULAR RESISTANCE;

ADMINISTRATION, ORAL; DOUBLE-BLIND METHOD; FEMALE; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; INTRAOPERATIVE PERIOD; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PROSPECTIVE STUDIES;

EID: 33751399398     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2006.08.035     Document Type: Article

References (30)

1. Simonneau G., Galie N., Rubin L.J., Langleben D., Seeger W., Domenighetti G., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 12 Suppl S (2004) 5S-12S
2. Christman B.W., McPherson C.D., Newman J.H., King G.A., Bernard G.R., Groves B.M., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
3. Stewart D.J., Levy R.D., Cernacek P., and Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med 114 (1991) 464-469
4. Ghofrani H.A., Pepke-Zaba J., Barbera J.A., Channick R., Keogh A.M., Gomez-Sanchez M.A., et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43 12 Suppl S (2004) 68S-72S
5. Raja S.G., and Nayak S.H. Sildenafil: emerging cardiovascular indications. Ann Thorac Surg 78 (2004) 1496-1506
6. Matsumoto T., Kobayashi T., and Kamata K. Phosphodiesterase in the vascular system. J Smooth Muscle Res 39 (2003) 67-86
7. Corbin J.D., and Francis S.H. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 56 (2002) 453-459
8. Stocker C., Penny D.J., Brizard C.P., Cochrane A.D., Soto R., and Shekerdemian L.S. Intravenous sildenafil and inhaled nitric oxide: a randomized trial in infants after cardiac surgery. Intensive Care Med 29 (2003) 1996-2003
9. Michelakis E.D., Tymchak W., Noga M., Webster L., Wu X.C., Lien D., et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108 (2003) 2066-2069
10. Galié N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
11. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105 (2002) 2398-2403
12. Wilkens H., Guth A., König J., Forestier N., Cremers B., Hennen B., et al. Effects of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104 (2001) 1218-1222
13. Cubillos-Garzón L.A., Casas J.P., and Morillo C.A. Sildenafil in secondary pulmonary hypertension. Int J Cardiol 89 (2003) 101-102
14. Ghofrani H.A., Wiedemann R., Rose F., Schemuly R.T., Olschewski H., Weissmann N., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 360 (2002) 895-900
15. Jackson G., Benjamin N., Jackson N., and Allen M.J. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83 (1999) 13C-20C
16. Ichinose F., Erana-Garcia J., Hromi J., Raveh Y., Jones R., Krim L., et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 29 (2001) 1000-1005
17. Trachte A.L., Labato E.B., Urdaneta F., Hess P.J., Klodell C.T., Martin T.D., et al. Oral sildenafil reduces pulmonary hypertension after cardiac surgery. Ann Thorac Surg 79 (2005) 194-197
18. Mangano D.T. Biventricular function after myocardial revascularization in humans: deterioration and recovery patterns during the first 24 hours. Anesthesiology 62 (1985) 571-577
19. Calvin Jr. J.E. Acute right heart failure: pathophysiology, recognition, and pharmacological management. J Cardiothorac Vasc Anesth 5 (1991) 507-513
20. Giad A., and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333 (1995) 214-221
21. Madden B.P., Sheth A., Ho T.B., Park J.E., and Kanagasabay R.R. Potential role for sildenafil in the management of perioperative pulmonary hypertension and right ventricular dysfunction after cardiac surgery. Br J Anaesth 93 (2004) 155-156
22. Cubillos-Garzon L.A., Casas J.P., and Morillo C.A. Sildenafil in secondary pulmonary hypertension. Int J Cardiol 89 (2003) 101-102
23. Lyon J.M., Duffy J.Y., Wagner C.J., and Pearl J.M. Sildenafil citrate alleviates pulmonary hypertension after hypoxia and reoxygenation with cardiopulmonary bypass. J Am Coll Surg 199 (2004) 607-614
24. Ockaili R., Salloum F., Hawkins J., and Kukreja R.C. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits. Am J Physiol Heart Circ Physiol 283; (2002) H1263-H1269
25. Tawakol A., Aziz K., Migrino R., Watkowska J., Zusman R., Alpert N.M., et al. Effects of sildenafil on myocardial blood flow in humans with ischemic heart disease. Coron Artery Dis 16 (2005) 443-449
26. Fung E., Fiscus R.R., Yim A.P., Angelini G.D., and Arifi A.A. The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest 128 (2005) 3065-3073
27. Rosengarten B., Schermuly R.T., Voswinckel R., Kohstall M.G., Olschewski H., Weissmann N., et al. Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. Cerebrovasc Dis 21 (2006) 194-200
28. Gillies H.C., Roblin D., and Jackson G. Coronary and systemic hemodynamic effects of sildenafil citrate: from basic science to clinical studies in patients with cardiovascular disease. Int J Cardiol 86 (2002) 131-141
29. Lobato E.B., Beaver T., Muehlschlegel J., Kirby D.S., Klodell C., and Sidi A. Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension. Br J Anaesth 96 (2006) 317-322
30. Ishikura F., Beppu S., Hamada T., Khandheria B.K., Seward J.B., and Nehra A. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation 102 (2000) 2516-2521